Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model
暂无分享,去创建一个
Sung-Hoon Jung | Manh-Cuong Vo | Je-Jung Lee | Je-Jung Lee | Hyun-ju Lee | Hyeoung-Joon Kim | Hyeoung-Joon Kim | Thanh-Nhan Nguyen-Pham | Hyun-Ju Lee | Thangaraj Jaya Lakshmi | Seoyun Yang | Manh-Cuong Vo | Thanh-Nhan Nguyen-Pham | Seoyun Yang | S. Jung | S. Jung
[1] Je-Jung Lee,et al. Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. , 2017, Experimental hematology.
[2] K. Alam,et al. A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model. , 2007, The Journal of surgical research.
[3] Z. Estrov,et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. , 2008, Blood.
[4] M. Caraglia,et al. Dendritic Cell-Mediated Cross-Presentation of Antigens Derived from Colon Carcinoma Cells Exposed to a Highly Cytotoxic Multidrug Regimen with Gemcitabine, Oxaliplatin, 5-Fluorouracil, and Leucovorin, Elicits a Powerful Human Antigen-Specific CTL Response with Antitumor Activity in Vitro1 , 2005, The Journal of Immunology.
[5] N. Hayashi,et al. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2‐derived peptide‐pulsed dendritic cell vaccines , 2007, Cancer.
[6] M. Czuczman,et al. Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model , 2005, Clinical Cancer Research.
[7] Je-Jung Lee,et al. Sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells , 2016, Experimental & Molecular Medicine.
[8] M. Czuczman,et al. Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo , 2007, British journal of haematology.
[9] J. Rhee,et al. Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity , 2015, Oncotarget.
[10] Je-Jung Lee,et al. Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma , 2015, Journal of immunotherapy.
[11] E. Gilboa,et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA , 1998, Nature Biotechnology.
[12] J. Whang‐Peng,et al. Generation of Carcinoembryonic Antigen (CEA)-Specific T-Cell Responses in HLA-A*0201 and HLA-A*2402 Late-Stage Colorectal Cancer Patients after Vaccination with Dendritic Cells Loaded with CEA Peptides , 2004, Clinical Cancer Research.
[13] J. Rhee,et al. Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist , 2010, Experimental & Molecular Medicine.
[14] Je-Jung Lee,et al. Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco/endoplasmic reticulum Ca(2+) transport ATPase 2 regulation. , 2015, Cytotherapy.
[15] E. Van Cutsem,et al. Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer , 2013, PloS one.
[16] K. Shortman,et al. Improving vaccines by targeting antigens to dendritic cells , 2009, Experimental & Molecular Medicine.
[17] A. Dalgleish,et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells , 2009, Cancer Immunology, Immunotherapy.
[18] M. Hanna,et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial , 1999, The Lancet.
[19] Je-Jung Lee,et al. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro. , 2014, Experimental hematology.
[20] I. Park,et al. Branched Polyethylenimine-Superparamagnetic Iron Oxide Nanoparticles (bPEI-SPIONs) Improve the Immunogenicity of Tumor Antigens and Enhance Th1 Polarization of Dendritic Cells , 2015, Journal of immunology research.
[21] Je-Jung Lee,et al. Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine. , 2014, Methods in molecular biology.
[22] Dr C. D. L. Reid. Dendritic cells and immunotherapy for malignant disease , 2001, British journal of haematology.
[23] M. Gordon. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .
[24] A. Naing,et al. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer , 2016, Cancer Chemotherapy and Pharmacology.
[25] Je-Jung Lee,et al. Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic , 2015, Chonnam medical journal.
[26] S. Burgdorf. Dendritic cell vaccination of patients with metastatic colorectal cancer. , 2010, Danish medical bulletin.
[27] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[28] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[29] A. Dalgleish,et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects , 2002, British Journal of Cancer.
[30] S. Kummar,et al. Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy. , 2008, Clinical colorectal cancer.